drugset / Trial / NCT00599872

Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies

NCT00599872 ↗

Phase 3 Completed 430 enrolled Greer Laboratories
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine an effective dose range for the administration of ragweed allergenic extract via the sublingual route of administration

Timeline

Start
2008-03
Primary completion
2008-11
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Standardized Ragweed Allergenic Extract Vaccine — Other

Indications